Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce the expansion of its existing multi-target collaboration and development agreement with LG Chem Life Sciences (LG Chem), the life sciences division of the South Korean LG Group, to include new programs incorporating Avacta’s Affimer XT™ serum half-life extension system.

In December 2018, Avacta and LG Chem entered into a multi-target therapeutics development agreement to develop Affimer therapeutics in several disease areas potentially worth over $300m to Avacta. The companies have today agreed to expand this drug development partnership to include Avacta’s Affimer XT technology, which can be used to control the time a drug spends in the circulation.

The expansion of the partnership includes an undisclosed additional upfront payment, plus near-term pre-clinical milestones and longer-term clinical development milestones totaling $98.5m for two therapeutics to be developed using the Affimer XT technology. Under the terms of the extended agreement, LG Chem has the exclusive rights to develop and commercialize, on a world-wide basis, Avacta’s Affimer PD-L1 inhibitor with Affimer XT serum half-life extension.

The expanded partnership also provides LG Chem with rights to develop and commercialize other Affimer and non-Affimer biotherapeutics combined with Affimer XT half-life extension for a range of indications and Avacta could earn up to $55m in milestone payments for each of these new products.

In addition, under the agreement Avacta will earn royalties on all future Affimer XT product sales by LG Chem.

I am delighted with this expansion to the agreement with LG Chem, with whom we have developed a strong collaborative partnership. LG Chem is a world-class drug development partner with excellent biologics manufacturing and clinical development capabilities and a pioneering vision to develop innovative therapies.

The expansion of our collaboration to develop new therapies for patients with cancer and other diseases is another strong validation of the Affimer technology and its potential as a therapeutic platform to deliver a pipeline of new drugs.

We look forward to developing these new therapies with our partners, LG Chem, and I look forward to updating the market on this and our other drug development and diagnostics progams in due course.”

Dr. Alastair Smith, Chief Executive, Avacta Group

This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (MAR).


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Avacta Life Sciences Ltd.. (2020, August 21). Avacta expands multi-target collaboration with LG Chem Life Sciences. News-Medical. Retrieved on July 18, 2024 from https://www.news-medical.net/news/20200821/Avacta-expands-multi-target-collaboration-with-LG-Chem-Life-Sciences.aspx.

  • MLA

    Avacta Life Sciences Ltd.. "Avacta expands multi-target collaboration with LG Chem Life Sciences". News-Medical. 18 July 2024. <https://www.news-medical.net/news/20200821/Avacta-expands-multi-target-collaboration-with-LG-Chem-Life-Sciences.aspx>.

  • Chicago

    Avacta Life Sciences Ltd.. "Avacta expands multi-target collaboration with LG Chem Life Sciences". News-Medical. https://www.news-medical.net/news/20200821/Avacta-expands-multi-target-collaboration-with-LG-Chem-Life-Sciences.aspx. (accessed July 18, 2024).

  • Harvard

    Avacta Life Sciences Ltd.. 2020. Avacta expands multi-target collaboration with LG Chem Life Sciences. News-Medical, viewed 18 July 2024, https://www.news-medical.net/news/20200821/Avacta-expands-multi-target-collaboration-with-LG-Chem-Life-Sciences.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test